There were 96 press releases posted in the last 24 hours and 170,826 in the last 365 days.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Mallinckrodt Public Limited Company (MNK) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

STEVENSON, Md., Feb. 15, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Columbia on behalf of purchasers of Mallinckrodt Public Limited Company (NYSE:MNK) (“Mallinckrodt” or the “Company”) securities during the period between November 25, 2014 and January 18, 2017, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until March 27, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Mallinckrodt securities during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that HP Acthar Gel’s (“Acthar”) monopoly status was the product of unlawful anticompetitive practices, and that increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers.

According to the complaint, following a November 9, 2016 article comparing the Company to Valeant Pharmaceuticals International, Inc., which was accused of fraud, a November 16, 2016 article accusing the Company of securities fraud, a November 29, 2016 announcement regarding the Company’s reliance on Medicare and Medicaid, and a January 18, 2017 announcement that the Company agreed to pay $100 million in connection with a joint settlement with the Federal Trade Commission and several states for its anticompetitive and unlawful practices, the value of Mallinckrodt shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Mallinckrodt securities purchased on or after November 25, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

/EIN News/ --

CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
hoffman@browerpiven.com

Distribution channels: Consumer Goods, Law